Filed Pursuant to Rule 424(b)(5)
Registration No. 333-283034
PROSPECTUS SUPPLEMENT
(To prospectus dated
November 6, 2024)
11,095,561 SHARES
COMMON STOCK
We have entered into an equity
distribution agreement with BTIG, LLC, Citizens JMP Securities, LLC and JonesTrading Institutional Services LLC as sales agents, or the Sales Agents, relating to shares of common stock, par value $0.01 per share, or our common stock, offered by this
prospectus supplement. We previously registered 18,000,000 shares of our common stock for sale through the sales agents pursuant to the terms of the equity distribution agreement. This prospectus supplement relates to the offer and sale from time to
time of the shares that remain unsold under such agreement.
Our common stock is listed on the New York Stock Exchange, or the NYSE, under the symbol
IVR. The last reported sale price of our common stock on the NYSE on December 13, 2024 was $8.48 per share.
Sales of the shares to
which this prospectus supplement and the accompanying prospectus relate, if any, will be made by means of ordinary brokers transactions on the NYSE or otherwise at market prices prevailing at the time of sale (which may be deemed to be
at the market offerings as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act) or negotiated transactions, or as otherwise agreed with the applicable Sales Agent, including in block transactions
or any other method permitted by law. The offering of common stock pursuant to the equity distribution agreement will terminate upon the earlier of (1) the sale of all the shares of our common stock subject to the equity distribution agreement,
and (2) the termination of the equity distribution agreement, pursuant to its terms, by either the Sales Agents or us. The Sales Agents will make all sales using commercially reasonable efforts consistent with their normal trading and sales
practices, on mutually agreed terms between the Sales Agents and us.
Under the terms of the equity distribution agreement, we also may sell shares to the
Sales Agents, as principal for their own accounts, at a price per share to be agreed upon at the time of sale. If we sell shares to any of the Sales Agents acting as principal, we will enter into a separate terms agreement setting forth the terms of
such transaction, and we will describe the terms agreement in a separate prospectus supplement or pricing supplement.
Each Sales Agent will be entitled
to compensation of up to 2.0% of the gross proceeds from the sale of the shares of our common stock sold through the Sales Agent under the equity distribution agreement, as further described herein under the caption Plan of Distribution.
In connection with the sale of shares of our common stock on our behalf, the Sales Agents may be deemed to be an underwriter within the meaning of the Securities Act and the compensation of the Sales Agents may be deemed to be
underwriting commissions or discounts.
To assist us in maintaining our qualification as a real estate investment trust, or REIT, for federal income tax
purposes, among other purposes, no person may own (or be treated as owning under applicable attribution rules) more than 9.8% by value or number of shares, whichever is more restrictive, of our outstanding shares of capital stock or common stock,
unless our board of directors waives this limitation. See Restrictions on Ownership and Transfer in the accompanying prospectus.
Investing in our common
stock involves a high degree of risk. Before buying any shares, you should read the discussion of material risks of investing in our common stock under the caption Supplemental Risk Factors beginning on page
S-6 of this prospectus supplement, in Item 1A of Part I beginning on page 9 of our Annual Report on Form 10-K for the year ended December 31, 2023, and risks
we disclose in future filings from time to time with the Securities and Exchange Commission, or the SEC.
Neither the SEC, any state securities
commission, nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus supplement and the accompanying prospectus to which it relates are truthful and complete. Any representation to the contrary
is a criminal offense.
|
|
|
|
|
|
|
|
BTIG |
|
Citizens JMP |
|
JonesTrading |
The date of this prospectus supplement is December 16, 2024.